PMLive1d
Pfizer/Arvinas’ vepdegestrant shows promise in phase 3 breast cancer study
The phase 3 VERITAC-2 trial has been evaluating the candidate against AstraZeneca’s endocrine therapy Faslodex (fulvestrant) ...
Pfizer (NYSE:PFE) To Divest Entire 7 Percent Stake In Haleon Through Share Offering
Pfizer (NYSE:PFE) announced its intention to sell its entire residual shareholding in Haleon plc, reflecting a divestment ...
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Nasdaq6d
The Zacks Analyst Blog Highlights Novo Nordisk, Roche, Pfizer, Arvinas and J&J
Pfizer and partner Arvinas announced mixed phase III data for breast cancer therapy, vepdegestrant. J&J and partner Protagonist Therapeutics' investigational targeted oral peptide, icotrokinra met ...
pharmaphorum2d
Pfizer's new drug data in breast cancer draws muted response
Pfizer has revealed that its much-anticipated ... Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared ...
Investing3d
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook
Arvinas has been exploring the potential of vepdegestrant in combination therapies. The company has shown promising results when combining vepdegestrant with Pfizer (NYSE:PFE)’s CDK inhibitors ...
Investing3d
Arvinas’s SWOT analysis: vepdegestrant potential drives stock outlook
In addition to the VERITAC-2 trial, Arvinas has been exploring the potential of vepdegestrant in combination therapies. The company has shown promising results when combining vepdegestrant with Pfizer ...
Reviewing Elevai Labs (NASDAQ:ELAB) & Arvinas (NASDAQ:ARVN)
Elevai Labs (NASDAQ:ELAB – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap multi-sector conglomerates companies, but which is the superior business? We will compare the ...